期刊
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
卷 35, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s13046-015-0276-9
关键词
Molecular targeted therapy; Gastric cancer; Monoclonal antibody; Tyrosine kinase inhibitor
类别
资金
- National Natural Science Foundation of China [81460377]
- Natural Science Foundation of Jiangxi Province, China [20142BAB215036, 20151BAB205041]
- Science and Technology Foundation of Department of Education of Jiangxi Province, China [GJJ14169]
- Graduate Student Innovation Foundation of Jiangxi Province, China [YC2015-B021]
- National Science and Technology Major Projects program for Major New Drugs Innovation and Development of China [2011ZX09302-007-03]
- Talent 555 Project of Jiangxi Province, China
Despite the global decline in the incidence and mortality of gastric cancer, it remains one of the most common malignant tumors of the digestive system. Although surgical resection is the preferred treatment for gastric cancer, chemotherapy is the preferred treatment for recurrent and advanced gastric cancer patients who are not candidates for reoperation. The short overall survival and lack of a standard chemotherapy regimen make it important to identify novel treatment modalities for gastric cancer. Within the field of tumor biology, molecular targeted therapy has attracted substantial attention to improve the specificity of anti-cancer efficacy and significantly reduce non-selective resistance and toxicity. Multiple clinical studies have confirmed that molecular targeted therapy acts on various mechanisms of gastric cancer, such as the regulation of epidermal growth factor, angiogenesis, immuno-checkpoint blockade, the cell cycle, cell apoptosis, key enzymes, c-Met, mTOR signaling and insulin-like growth factor receptors, to exert a stronger anti-tumor effect. An in-depth understanding of the mechanisms that underlie molecular targeted therapies will provide new insights into gastric cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据